medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2015, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (4)


Trombosis y trasplante de progenitores hematopoyéticos: patogénesis y complicaciones trombóticas más frecuentes

Roque GW, Jaime FJC

Idioma: Español
Referencias bibliográficas: 61
Paginas: 349-361
Archivo PDF: 111.69 Kb.


RESUMEN

Las complicaciones trombóticas son comunes en el contexto del trasplante de células progenitoras hematopoyéticas. El daño al endotelio vascular aparece como el factor desencadenante en la cascada de evento que conlleva a la trombosis en el paciente trasplantado. Estas complicaciones son diversas y aparecen en las fases inmediatas o tardías. El síndrome de obstrucción sinusoidal hepático, caracterizado por trombosis en los pequeños vasos de la microcirculación, constituye la complicación más frecuente y mejor estudiada. En este trabajo se revisa la patogénesis de las complicaciones trombóticas en el paciente con trasplante de células progenitoras hematopoyéticas y se describen las más frecuentes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med. 2006;354(17):1813-26.

  2. Graf l, Stern M. Acute phase after haematopoietic stem cell transplantation: bleeding and thrombotic complication. Hamostaseologie. 2012;32(1):56-62.

  3. Zeidan AM, Wellman J, Forde PM, Bolaños-Meade J, Streiff MB. Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers. J Thromb Thrombolysis. 2014 May;37(4):524-6. doi: 10.1007/s11239-013-1002-0.

  4. Rovó A, Tichelli A. Cardiovascular complications in long term survivors after allogeneic haematopoietic stem cell transplantation. Semin Hematol. 2012;49(1):25-34.

  5. Debordeau P, Farge D, Beckers M, Baglin C, Bauersachs MR, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheter in patients with cancer. J Thromb Haemost.2013,11(1):71-80.

  6. Duarte M, Batista J, Arbo A. Trombosis asociada a cateter venoso central: reporte de caso. Rev Inst Med Trop. 2010;5(1):35-8.

  7. Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, et al. Analysis of incidence, risk factor and clinical outcome of thromboemblic and bleeding events in 431 allogeneic haematopoietic stemcell transplantation recipients. Haematologica. 2013;98(3):437-43.

  8. Brandao LR, Kletzel M, Boulad F, Kurtzberg J, Maloney K, FligmanI, et al. A prospective longitudinal multicenter study of coagulation in paediatrics patients undergoing stem cell transplantation. Pediatr Blood Cancer. 2008;50:1240-6.

  9. Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B, et al. Endhotelial cells derived-microparticles in allogeneic hematopoietic stem cell recipients. Transplantation. 2006;81(10):1405-9.

  10. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, et al. Cyclosporine induces endothelial cell releases of complement-activating microparticles. J Am Soc Nephrol. 2013;24(11):1849-62.

  11. Nadir Y, Brener B. Thrombotic complications associated with stem cell transplantation. Blood Reviews. 2012;26(5):183-87.

  12. Aird WC. Endothelium in health and disease. Pharmacol Rep. 2008;60:139-43.

  13. Tichelli A, Gratwohl A. Vascular endothelium as novel target of graft versus host disease. Best Pract Res Clin Haematol. 2008;21(2):139-48.

  14. Carreras E, Diaz.-Ricart M. The role of the endothelium in the short - term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495-02.

  15. Richard S, Seigneur M, Blann A, Adams R, Renard M, Puntous M, et al. Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18(5):955-9.

  16. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, BandiniG, et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant. 1996;17:277-80.

  17. Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010;16(8):1180-85.

  18. Palomo M, Díaz- Ricart M, Carbo C, Rovira M, Fernández-Aviles F, Escobar G, et al. The release of soluble factors contributing to endothelial activation and damageafter hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant. 2009;15(5):537-46.

  19. Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H, et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic stem cell transplantation. Blood. 2004;103(9):1015-23.

  20. Jacobs P, Miller JL, Uys CJ, Dietrich BE. Fatal veno-occlusive disease of the liver after chemotherapy, whole body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J. 1979;55(1):5-10.

  21. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27-42.

  22. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-68.

  23. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52.

  24. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014 Dec;4(4):332-46. doi:10.1016/j.jceh.2014.10.002.

  25. Chao N. How I treat sinusoidal obstruction syndrome. Blood. 2014;123(26):4023-26.

  26. Chevallier P, Prebet T, Turlure P, Hunault M, Vigouroux S, Harousseau JL, et al. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(1):165-70.

  27. Carreras E. Prevención y tratamientode la enfermedad venooclusiva hepática. Gastroenterol Hepatol. 2011;34(9):635-40.

  28. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood. 1992;79(11):2834-40.

  29. Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol. 1991;47(5):346-54.

  30. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant. 2003;31(12):1143–9.

  31. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematicreviewof controlled clinical trials on the use of ursodeoxycholicacid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant.2007;13(2):206-217.

  32. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977-83.

  33. Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, Lipton JM. Low incidence of hepatic veno-occlusive disease in paediatrics patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. Pediatr Transplant. 2010;14(5):618-21.

  34. Ringdén O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25(9):993-6.

  35. Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic venoocclusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006; 91(6):795-800.

  36. Morabito F, Gentile M, Gay F, Bringhen S, Mazzone C, Vigna E, et al. Insights into defibrotide: an updated review. Expert Opin Biol Ther. 2009; 9(6): 763–72.

  37. Park M, Park HJ, Eom H-S, Kwon YJ, Park JA, Lim YJ, et al. Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation. Ann Transplant. 2013;18:36-42.

  38. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et-al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant.2010; 16(7):1005-17.

  39. Cappelli B, Chiesa R, Evangelio C, Biffi A, Roccia T, Frugnoli I, et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulfan. Br J Haemat. 2009;147(4):554-60.

  40. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004:33(2):89-95.

  41. Bagal B, Choughale A, Khattry NN. Low dose defibrotide for management of hepatic veno-occlusive disease.Biol Blood Marrow Transplant. 2014;20(2):190-1.

  42. Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Arai S, et al. Defibrotide Study Group Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol. Blood. 2013;122(21):1-17.

  43. Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, et-al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(9):785-90.

  44. Pihusch R, Salat C, Schmidt E, Goring P, Pihusch M, Hiller E, et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation. 2002;74(9):1303-09.

  45. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G , Kapsimal V, et al. Association between the plasminogen activator inhibitor 1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost. 2007;97(6):907-13.

  46. Ruutu T, Barosi G, Benjamin RJ, Clark RE, GeorgeJN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplantation-associated microangiopathy: results of consensus process by an International Working Group. Haematologica. 2007;92(1):95-100.

  47. Stavrou E, Lazarus HM. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis. 2010;2(3):e2010033. doi:10.4084/MJHID.2010.033.

  48. Martinez MT, Bucher CH, Stussi G, Heim D, Busser a, Tsakiris DA, et al. Transplant-associated microangiopathy (MAT) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplantat. 2005;36(11):993-1000.

  49. Corti P, Uderzo C, Tagliabue A, Della Volpe A, Annaloro C, Tagliaferri E, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;29(6):542-43.

  50. Alessandrino EP, Martinelli G, Canevari A, Bernasconi P, Caldera D, Colombo A, et al. Prompt response to high dose intravenous immunglobulins given as first line therapy in post-transplant thrombotic thrombocytopenic purpura. Bone Marrow Transplant. 2000;25(11):1217-8.

  51. Boersma RS, Jie K-SG, Verbon A,van Pampus ECM, Schouten HC. Thrombotic and infectious complications of central venous catheters in patients with haematological malignancies. Ann Oncol. 2008;19(3):433–42.

  52. Pihusch M, Lohse P, Reitberger J, Hiller E, Reihhard A, Hans-Jochem A, et al. Impact of thrombophilic gene mutations and graft versus host-disease on thromboembolic complications after allogeneic hematopoietic stem cell transplantation. Transplantation. 2004;78(6):911-8.

  53. Gonsalves A, Carrier M, Wells PS, McDiarmid A, Huebsch LB, Allan DS. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Trhromb Haemost. 2008;6(9):1668-73.

  54. Nadir Y, Brenner B. Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res. 2007;120:Supl 2:92–8.

  55. Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie. 2012;32(2):132-7.

  56. Wilbur J, Shian B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Pham Physician. 2012;86(10):913-19.

  57. Aghajanzadeh D, Gassanov N, Schmidt M, Semmo N, Er F. Imaging techniques for the diagnosis of pulmonary embolism. Rep Med Imaging. 2010;3(13):129-39.

  58. Marchick MR, Courtney MD, Kabrhel C, Nordenholz KE, Plewa MC, Richman PB, et al. 12 lead ECG findings of pulmonary hypertension occur more frequently in emergency department patients with pulmonary embolism than in patients without pulmonary embolism. Ann Emerg Med. 2010;55(4):331-5.

  59. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2012;141(2)(Suppl):7S–47S.

  60. Armenian SH, Sun C-L, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular risk factors in hematopoietic stem cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012;120(23):4505-12.

  61. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463–71.




2020     |     www.medigraphic.com